MA34753B1 - Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes - Google Patents

Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes

Info

Publication number
MA34753B1
MA34753B1 MA36032A MA36032A MA34753B1 MA 34753 B1 MA34753 B1 MA 34753B1 MA 36032 A MA36032 A MA 36032A MA 36032 A MA36032 A MA 36032A MA 34753 B1 MA34753 B1 MA 34753B1
Authority
MA
Morocco
Prior art keywords
methods
compositions
treatment
clinical applications
indifferentiated
Prior art date
Application number
MA36032A
Other languages
English (en)
Inventor
Timothy W Starzl
Original Assignee
Pantheryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantheryx Inc filed Critical Pantheryx Inc
Publication of MA34753B1 publication Critical patent/MA34753B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions et des procédés améliorés pour l'immunisation passive. Certains modes de réalisation de l'invention concernent une composition contenant une combinaison synergique d'anticorps polyclonaux spécifiques dans une matrice de support. L'invention concerne en outre des compositions et des procédés efficaces et économiques pour le traitement de la diarrhée et des infections entériques dans des applications cliniques à large spectre, indifférenciées ou mixtes.
MA36032A 2010-11-23 2013-06-21 Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes MA34753B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41666710P 2010-11-23 2010-11-23
PCT/US2011/061708 WO2012071346A1 (fr) 2010-11-23 2011-11-21 Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes

Publications (1)

Publication Number Publication Date
MA34753B1 true MA34753B1 (fr) 2013-12-03

Family

ID=46146180

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36032A MA34753B1 (fr) 2010-11-23 2013-06-21 Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes

Country Status (28)

Country Link
US (3) US9701735B2 (fr)
EP (2) EP3424531A1 (fr)
JP (2) JP6121907B2 (fr)
KR (2) KR102037885B1 (fr)
CN (2) CN105012950A (fr)
AP (1) AP2013006940A0 (fr)
AR (1) AR083973A1 (fr)
AU (3) AU2011332053B2 (fr)
BR (1) BR112013012594A2 (fr)
CA (1) CA2818827C (fr)
CL (1) CL2013001469A1 (fr)
CO (1) CO6791606A2 (fr)
DK (1) DK2643017T3 (fr)
EA (1) EA034057B1 (fr)
ES (1) ES2742734T3 (fr)
HK (1) HK1216616A1 (fr)
IL (2) IL226475A0 (fr)
MA (1) MA34753B1 (fr)
MX (2) MX340019B (fr)
MY (1) MY164281A (fr)
NZ (2) NZ612299A (fr)
PE (1) PE20141173A1 (fr)
PH (2) PH12013501040A1 (fr)
PT (1) PT2643017T (fr)
SG (2) SG10201509584UA (fr)
TW (2) TWI656881B (fr)
UA (1) UA115524C2 (fr)
WO (1) WO2012071346A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140017257A1 (en) * 2012-07-11 2014-01-16 Xi Jiang IgY From Norovirus P Particles And Their Derivatives
US9458230B2 (en) * 2013-01-04 2016-10-04 Wisconsin Alumni Research Foundation Secretory IGA compositions, methods of making and methods of use thereof
US9321803B2 (en) 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
CN104829713A (zh) * 2014-05-27 2015-08-12 青岛大学附属医院 特异性抗镰刀菌感染的鸡卵黄抗体的制备和应用
EA201790558A1 (ru) * 2014-10-15 2017-08-31 Ксенотера Композиция с пониженной иммуногенностью
US11168127B1 (en) * 2015-12-01 2021-11-09 Camas Incorporated Pathogen specific avian antibodies in the neonatal mammal
US10632158B2 (en) 2016-06-23 2020-04-28 IgY Nutrition Use of a hyperimmune egg product to prevent and treat dysbiosis
CA3062868A1 (fr) * 2016-08-01 2018-02-08 Scaled Microbiomics, Llc Systemes et procedes de modification du microbiome pour reduire le risque de maladie et les manifestations de la maladie
WO2018182983A1 (fr) 2017-03-28 2018-10-04 Children's Hospital Medical Center Vaccins à base de particules s de norovirus et leurs procédés de fabrication et d'utilisation
WO2019087372A1 (fr) 2017-11-02 2019-05-09 オーストリッチファーマ株式会社 Anticorps d'autruche pour infection bactérienne
CA3084954A1 (fr) 2017-12-05 2019-06-13 BioPlx, Inc. Procedes et compositions pour prevenir une infection microbienne
CN109908344A (zh) * 2017-12-12 2019-06-21 广州汇高生物科技有限公司 一种用于治疗溃疡性结肠炎的药物组合物及其制备方法
WO2020072636A1 (fr) * 2018-10-03 2020-04-09 Anubis Bio Corporation Composition et méthodes de traitement de la diarrhée aiguë et entérique
WO2020132296A1 (fr) * 2018-12-20 2020-06-25 Pantheryx, Inc. Composition de produit de nutrition médical pour diarrhées aiguës
WO2020176637A1 (fr) 2019-02-26 2020-09-03 Pantheryx, Inc. Compositions pour la gestion de troubles du tractus gastro-intestinal
WO2020237023A1 (fr) * 2019-05-21 2020-11-26 Scaled Microbiomics, Llc Formulations destinées à la modification du microbiome pour réduire les risques de cancers colorectaux héréditaires et spontanés
US12194096B2 (en) 2019-10-31 2025-01-14 Stevens Law Group Composition and methods for preventing and treating African swine fever in wild and domestic swine
WO2021168321A1 (fr) * 2020-02-19 2021-08-26 Anubis Bio Corporation Composition et procédés de traitement d'agents infectieux au moyen d'anticorps spécifiques aux pathogènes
EP4125965A4 (fr) * 2020-04-03 2024-04-24 University of Utah Research Foundation Méthode de traitement d'une maladie pulmonaire avec un liquide amniotique acellulaire
WO2021205408A1 (fr) * 2020-04-10 2021-10-14 Igy Immune Technologies And Life Sciences Inc. Immunoglobulines igy ciblant le coronavirus, procédés pour les préparer, et procédés les utilisant
CA3175504A1 (fr) * 2020-04-14 2021-10-21 Julius G. GOEPP Traitement ou prevention de la diarrhee des voyageurs
CN111803628B (zh) * 2020-07-24 2021-05-14 尤丽康（江苏）生物医药有限公司 一种抗幽门螺杆菌复合制剂
WO2022103871A1 (fr) * 2020-11-10 2022-05-19 Wyomingv Immune, Inc. Compositions thérapeutiques pour le traitement de la covid-19
IL307440B2 (en) * 2021-04-16 2025-12-01 Prodigy Biotech Hyperimmunized egg product for treating or preventing alcoholic liver disease and graft-versus-host disease
US11319382B1 (en) 2021-06-28 2022-05-03 King Abdulaziz University Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection
TW202444746A (zh) * 2023-05-03 2024-11-16 財團法人國家衛生研究院 治療及／或預防諾羅病毒感染之免疫球蛋白ｙ組合物
AU2024219856B2 (en) * 2023-05-10 2025-10-23 Koru Biotech Solutions Limited Therapeutic agents and compositions and related methods
WO2025062506A1 (fr) * 2023-09-19 2025-03-27 有限会社バイオメディカルリサーチグループ Lipopolysaccharide, procédé de production de lipopolysaccharide et produit mélangé à un lipopolysaccharide
WO2025259740A1 (fr) * 2024-06-12 2025-12-18 Elanco Us Inc. Compositions de lysozyme et procédés associés
WO2026072929A1 (fr) 2024-09-27 2026-04-02 Pantheryx, Inc. Compositions pour le traitement des effets secondaires gastro-intestinaux des médicaments pour la perte de poids et le diabète

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US4550019A (en) 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US4377569A (en) 1980-01-21 1983-03-22 Plymate Robert R Method of treating animals to resist infectious diseases
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4341763A (en) * 1981-03-10 1982-07-27 Smithkline-Rit Methods of vaccinating humans against rotavirus infection
NZ201698A (en) 1981-08-31 1985-12-13 S L Gaffin Composition of antibodies specific to endotoxins
US4748018A (en) 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4816563A (en) 1983-11-25 1989-03-28 Amtron, Inc. Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof
JPS60123428A (ja) 1983-12-05 1985-07-02 Green Cross Corp:The 下痢症治療剤
US5198213A (en) 1985-04-15 1993-03-30 Protein Technology, Inc. Method of disease treatment utilizing an immunologically whey fraction
CH0225254H1 (en) 1985-11-25 1998-09-15 Ghen Corp Specific antibody-containing substance from eggs and method of production and use thereof
IT1204777B (it) 1986-02-04 1989-03-10 Crinos Industria Farmaco Composizione per la preparazione estemporanea di formulazioni per applicazioni topiche per uso farmaceutico e cosmetico
US5017372A (en) 1986-04-14 1991-05-21 Medicis Corporation Method of producing antibody-fortified dry whey
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
DE58904683D1 (de) 1988-04-19 1993-07-22 Biotest Pharma Gmbh Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen.
US5719267A (en) 1989-10-31 1998-02-17 Ophidian Pharmaceuticals Inc. Clostridial toxin disease therapy
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
DK0537280T3 (da) 1990-07-02 1997-10-13 Nat Jewish Ct Immun & Respirat Fremstilling og anvendelse af transfer-faktor
US5258178A (en) 1990-07-30 1993-11-02 Abbott Laboratories Method and product for the treatment of gastric disease
US5753228A (en) 1992-08-25 1998-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Method of treating parasitosis by the enteral administration of hyperimmune hen egg yolk antibodies
US5367054A (en) 1993-04-12 1994-11-22 Stolle Research & Development Corp. Large-scale purification of egg immunoglobulin
US5585098A (en) 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
US5876735A (en) 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
AU729502B2 (en) 1996-10-02 2001-02-01 Ovimmune, Inc. Oral administration of chicken yolk antibodies to treat disease
SE9701026D0 (sv) 1997-03-20 1997-03-20 Immun System Ims Ab use of avian antibodies
JPH10265393A (ja) 1997-03-25 1998-10-06 Natl Fedelation Of Agricult Coop Assoc 豚流行性下痢の予防治療剤
JP3430853B2 (ja) 1997-04-11 2003-07-28 株式会社ゲン・コーポレーション 胃炎、胃潰瘍および十二指腸潰瘍の予防剤並びに治療剤
US6616927B2 (en) 1997-05-29 2003-09-09 Agresearch Limited Processes for production of immunoglobulin A in milk
US5846569A (en) 1997-06-20 1998-12-08 Creative Labs, Inc. Colostrum supplement
IE970541A1 (en) 1997-07-25 1999-01-27 Michael Anthony Folan Maternal immune secretions and their use in the treatment and/or prophylaxis of the buccal cavity
CZ287956B6 (cs) 1997-11-04 2001-03-14 Medipharm Cz, S. R. O. Perorální přípravek k prevenci a léčbě parvovirózy psů
CN1290580C (zh) * 1998-04-01 2006-12-20 中德联合研究院 抗轮状病毒鸡卵黄免疫球蛋白产品
ATE298199T1 (de) 1998-04-29 2005-07-15 Fonnelop Kare Verfahren zur herstellung von kolostrum
AU4376199A (en) 1998-06-26 2000-01-17 Pasteur Merieux Serums Et Vaccins Mucosal targeting immunisation
US6258383B1 (en) 1998-08-14 2001-07-10 Lactoferrin Products Company Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
WO2000019843A1 (fr) 1998-10-01 2000-04-13 Canadian Inovatech Inc. Produit concentre d'oeuf
US6379676B2 (en) 1999-03-10 2002-04-30 Anitox Corporation Enhancing immune response in animals
US6348223B1 (en) 1999-06-29 2002-02-19 Rose Acre Farms, Inc. Milk replacer composition and method
WO2001072141A2 (fr) 2000-03-24 2001-10-04 Trouw Nutrition Usa Combinaison de produits de plasma et de produits hyperimmunises destinee a une meilleure performance
CN1218751C (zh) * 2000-08-31 2005-09-14 北京好友巡天生物技术有限责任公司 二元活性抗体制剂及其制备方法
CA2357685A1 (fr) 2000-09-18 2002-03-18 Chisolm Biological Laboratory, Llc Composition de facteur de transfert et methode de production de cette composition
US6468534B1 (en) 2000-09-21 2002-10-22 4Life Research, Lc Methods for obtaining transfer factor from avian sources, compositions including avian-generated transfer factor, and methods of use
WO2002053179A1 (fr) 2001-01-05 2002-07-11 Egg Biotech Incorporation Procede de production d'un oeuf contenant des anticorps (igy) specifiques de bacteries anti-pathogenes et yoghourt et creme glacee contenant ces igy
US7244427B2 (en) 2001-01-30 2007-07-17 The Lauridsen Group Incorporated Isolated bovine IgG heavy chain protein and its use as an antimicrobial
US6939954B2 (en) 2001-01-30 2005-09-06 The Lauridsen Group Incorporated Isolated bovine lgG heavy chain protein and its use as an antimicrobial
CA2339436A1 (fr) 2001-03-15 2002-09-15 Josee Harel Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation
US6932967B2 (en) 2001-03-22 2005-08-23 Michael R. Simon Human medical treatment by aerosol inhalation of immunoglobulin A
KR20040106298A (ko) * 2002-03-21 2004-12-17 아나디스 리미티드 불안정한 생활성 물질 및 포유동물 초유를 포함한 조성물,제조 및 치료 방법
CA2486801A1 (fr) 2002-05-21 2003-11-27 Anadis Ltd Methode de prophylaxie d'infections
WO2004017916A2 (fr) 2002-08-22 2004-03-04 4Life Research, Lc Composition therapeutique cardiovasculaire comprenant un facteur de transfert et methodes therapeutiques comprenant l'utilisation de ladite composition
JP4556407B2 (ja) 2002-10-04 2010-10-06 住友金属鉱山株式会社 酸化物透明電極膜とその製造方法、透明導電性基材、太陽電池および光検出素子
SE0203265D0 (sv) 2002-11-06 2002-11-06 Coloplus Ab A feed or food product composition
US20060233781A1 (en) 2003-01-02 2006-10-19 Pedersen Medical A/S Antimicrobial composition for local use on mucosal membranes and skin
SE0300213D0 (sv) 2003-01-30 2003-01-30 Immun System Uppsala I M S Ab Use of avian antibodies
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
US6866868B1 (en) 2003-09-15 2005-03-15 4Life Research, Lc Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
EP1723951A1 (fr) 2005-04-21 2006-11-22 N.V. Nutricia Supplément nutritionnel avec des oligosaccharides pour une catégorie de patients avec HIV
PT1629850E (pt) 2004-08-24 2007-08-14 Nutricia Nv Composição nutricional que compreende a administração de oligossacarídeos indigeríveis
EP1799252A4 (fr) 2004-10-06 2009-01-21 Agri Biotech Pty Ltd Méthode de production d'anticorps
AP2007004019A0 (en) 2004-11-25 2007-06-30 Unilever Plc Heavy chain and single domain antibodies
CN101242748A (zh) 2004-11-26 2008-08-13 荷兰纽迪希亚公司 含有蛋白酶抑制剂的婴儿营养品
US10471100B2 (en) 2006-09-29 2019-11-12 4Life Patents, Llc Nanofraction immune modulators, preparations and compositions including the same, and associated methods
ZA200800978B (en) 2005-08-19 2009-08-26 Unilever Plc Food products comprising probiotic micro-organisms and antibodies
US20070264264A1 (en) * 2005-08-30 2007-11-15 La Belle Associates, Inc. Method and composition for conferring immunity in mammals
CA2521156A1 (fr) 2005-09-16 2007-03-16 John Hare Anticorps en tant qu'agents favorisant la croissance
CN1965665A (zh) * 2005-11-16 2007-05-23 雅臣药业集团（远东）有限公司 IgY抗体免疫奶或奶粉的制备方法
EP1998800A2 (fr) * 2006-01-18 2008-12-10 University Of Chicago Compositions et procédés se rapportant à des protéines de bactéries staphylococciques
WO2007108541A1 (fr) 2006-03-23 2007-09-27 Senju Pharmaceutical Co., Ltd. Composition ophtalmique comprenant de la gomme de xanthane et du glucose
US20090053197A1 (en) 2006-06-14 2009-02-26 Ramaekers Joseph C Transfer Factor Compositions and Methods
US20080031903A1 (en) 2006-07-27 2008-02-07 Andrea Gambotto Method of treating ocular infections
CN101626784B (zh) 2006-08-31 2013-07-17 作为康可信托公司受托人的A.C.N.135493391股份有限公司 利用包含抗体的组合物治疗和/或预防非传染性医学病症
WO2009020748A2 (fr) 2007-07-16 2009-02-12 Avaxia Biologics, Inc. Thérapie par anticorps pour moduler la fonction de récepteurs intestinaux
JP2010536932A (ja) 2007-08-30 2010-12-02 ベンクト・オーゲルプ 真菌感染を治療および予防するための、ニワトリ卵黄免疫グロブリン（ＩｇＹ）の局所投与
EP2244735A4 (fr) 2007-10-02 2011-02-23 Avaxia Biologics Inc Thérapie aux anticorps pour une utilisation dans le tube digestif
EP2058001A1 (fr) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Amélioration de l'immunogénicité des antigènes
NZ587901A (en) 2008-03-13 2012-11-30 Immuron Ltd Immuno-modulating compositions for the treatment of immune-mediated disorders
WO2009127519A1 (fr) 2008-04-18 2009-10-22 Unilever Nv Compositions comprenant des anticorps ou des fragments d'anticorps
WO2010044095A2 (fr) 2008-09-04 2010-04-22 Pawan Saharan Nouveaux fragments peptidiques actifs de maniere immunologique d'un polypeptide riche en proline isole a partir de colostrums de mammifere pour le traitement de maladies ou d'affections virales et non-virales
EP3461840A1 (fr) 2009-04-27 2019-04-03 Immuron Limited Préparation d'immunoglobuline enrichie en anti-lps destinée au traitement et/ou à la prophylaxie de la stéatohépatite non alcoolique
US8211435B2 (en) * 2009-06-09 2012-07-03 Hamid Reza Rahmani Calf biologic anti-scour supplement (CBAS)
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US20110129479A1 (en) 2009-12-02 2011-06-02 Tobin Monte B Immunogen selection directed in immunoglobulin packages in plasma and colostrum and method of making and using same

Also Published As

Publication number Publication date
AU2016201651B2 (en) 2018-02-22
NZ612299A (en) 2016-01-29
CN105012950A (zh) 2015-11-04
MX340019B (es) 2016-06-22
TW201300126A (zh) 2013-01-01
AU2016201651A1 (en) 2016-04-07
US20200299360A1 (en) 2020-09-24
ES2742734T3 (es) 2020-02-17
EA201370127A1 (ru) 2013-09-30
AR083973A1 (es) 2013-04-10
US9701735B2 (en) 2017-07-11
US10611828B2 (en) 2020-04-07
CN103533958A (zh) 2014-01-22
PH12013501040A1 (en) 2022-10-24
KR102037885B1 (ko) 2019-10-30
KR20190003798A (ko) 2019-01-09
MY164281A (en) 2017-11-30
HK1216616A1 (zh) 2016-11-25
CA2818827C (fr) 2024-02-13
PE20141173A1 (es) 2014-09-25
EP2643017A4 (fr) 2015-08-05
TW201630624A (zh) 2016-09-01
EP2643017A1 (fr) 2013-10-02
NZ709245A (en) 2016-11-25
AU2018203497B2 (en) 2020-05-07
CA2818827A1 (fr) 2012-05-31
AU2018203497A1 (en) 2018-06-07
WO2012071346A1 (fr) 2012-05-31
CL2013001469A1 (es) 2014-03-07
US20170327564A1 (en) 2017-11-16
PH12018501891A1 (en) 2019-03-11
EP2643017B1 (fr) 2019-05-22
AU2011332053A1 (en) 2013-05-02
PT2643017T (pt) 2019-09-05
IL261338A (en) 2018-10-31
CN103533958B (zh) 2015-07-08
MX2013005704A (es) 2013-10-01
IL226475A0 (en) 2013-07-31
JP2017075150A (ja) 2017-04-20
EA034057B1 (ru) 2019-12-23
TWI656881B (zh) 2019-04-21
IL261338B (en) 2019-11-28
CO6791606A2 (es) 2013-11-14
DK2643017T3 (da) 2019-08-26
AP2013006940A0 (en) 2013-06-30
BR112013012594A2 (pt) 2018-10-16
TWI539964B (zh) 2016-07-01
AU2011332053B2 (en) 2016-06-02
UA115524C2 (uk) 2017-11-27
JP2013543895A (ja) 2013-12-09
MX355905B (es) 2018-05-04
EP3424531A1 (fr) 2019-01-09
SG10201509584UA (en) 2015-12-30
KR20140043303A (ko) 2014-04-09
JP6121907B2 (ja) 2017-04-26
SG190384A1 (en) 2013-06-28
US20120141458A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
PH12018501891A1 (en) Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
EP1575509A4 (fr) Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci
MA32577B1 (fr) Anticorps neutralisants le virus de l'influenza a et leurs utilisations
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
MA64193B1 (fr) Anticorps bispécifiques se liant aux dll3 et cd3
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
MA31606B1 (fr) Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation
BR112013008140A2 (pt) "compostos imidazotriazinona".
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MA38176A1 (fr) Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA34641B1 (fr) Anticorps anti-il-23
BRPI0506726B8 (pt) anticorpo monoclonal específico para m-csf e usos deste
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
MA34724B1 (fr) Nouvelle forme d'administration d'un inhibiteur de l'enképhalinase
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
FR2992973A1 (fr) Nouvelle souche de lactobacillus crispatus
MA33839B1 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs
CR10561A (es) Vacunas para malaria
MA38161A1 (fr) Anticorps anti-bmp-6